Business Of Biotech Matt Pillar

We love to hear from our listeners. Send us a message.Back by popular demand, biopharma industry opinionator extraordinaire Allan Shaw rejoins the Business of Biotech to expose the murky role Pharmacy Benefit Managers (PBMs) play in the last, costly mile of the drug distribution supply chain. Allan pulls no punches in his criticism of the current rebate structure and shares why the model leaves patients and manufacturers stuck with the spiraling tab. He also explains why an election year, all...

We love to hear from our listeners. Send us a message.From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in global tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a leader at Tecnomatix, which sold to UGS and was acquired by Siemens. Those big deals that came on the heels of several other Yochi Slonim software s...

We love to hear from our listeners. Send us a message.As if Orna Therapeutics' CEO Thomas Barnes, CEO isn't a enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to biotech, the therapeutic proposition of circular, or "O" RNA and why it holds great potential to best linear RNA constructs, the novel, platform...

We love to hear from our listeners. Send us a message.Novel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Sounds rational, but it’s actually a unique perspective in a platform-crazed biotech industry. Dr. Kakkar’s worldview is shaped by his work as a physician—work he continues at Brigham and Women’s Hospital even as he builds Tome Biosciences, where he serves as President & CEO. Tome, which is developing programmable genomic integration technology, is t...

We love to hear from our listeners. Send us a message.This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team at ImmunityBio are doing to change that standard of care. They're painfully close. Dr. Reddy, Chief Medical Officer at ImmunityBio, gives us a long look behind the curtain at the commercial preparations the company is making as its lead Phase 3 candidate,...

We love to hear from our listeners. Send us a message.Ampersand Biomedicines CEO Jason Gardner, D.Phil. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he's seen most of the ups and the downs that come with biotech leadership, and in his latest venture with the Flagship Pioneering-backed Ampersand, he's putting all those hard-fought lessons to good use. On this episode of the Business of Biotech -- the fi...